Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ALVO Alvotech
12.850+0.070+0.55%
Close
02/07 16:00 ET
12.8500.0000.00%
Post Mkt Price 02/07 16:00 ET
High
12.950
Open
12.840
Turnover
1.74M
Low
12.800
Pre Close
12.780
Volume
134.95K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair
Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand
Sector Update: Health Care Stocks Flat to Lower Pre-Bell Tuesday
09:10 AM EST, 01/24/2023 (MT Newswires) -- Health care stocks were flat to lower pre-bell Tuesday. The iShares Biotechnology ETF (IBB) was inactive and the Health Care Select Sector SPDR Fund (XLV) wa
Alvotech, Bioventure Get Approval for Humira Biosimilar in Saudi Arabia
Alvotech: Plan to Use Net Proceeds From Private Placement Offering for General Purposes >ALVO
Alvotech: Completed $137M Private Share Placement
Alvotech Completes $137 Million Private Placement
03:21 AM EST, 01/23/2023 (MT Newswires) -- Biotech company Alvotech (ALVO.IC) said Monday it completed a private placement of around $137 million of its ordinary shares in an overseas directed offerin
Alvotech (NYSE:ALVO) Trading Down 0.4%
Alvotech (NYSE:ALVO – Get Rating)'s share price traded down 0.4% on Wednesday . The stock traded as low as $12.28 and last traded at $12.35. 77,686 shares were traded during mid-day trading, a decli
Alvotech's (NASDAQ:ALVO) Largest Shareholders Are Private Equity Firms Who Were Rewarded as Market Cap Surged US$158m Last Week
A look at the shareholders of Alvotech (NASDAQ:ALVO) can tell us which group is most powerful. With 42% stake, private equity firms possess the maximum shares in the company. In other words, the gr
Alvotech, Fuji Pharma Expand Pact by Adding New Potential Biosimilar
Alvotech Begins Pharmacokinetic Study for Potential Biosimilar to Anti-Inflammatory Drug Simponi
04:57 AM EST, 01/11/2023 (MT Newswires) -- Alvotech (ALVO) said Wednesday it has begun a pharmacokinetic study for AVT05, a potential biosimilar to anti-inflammatory drugs Simponi and Simponi Aria. Al
Company Overview
More
Alvotech (formerly Oaktree Acquisition Corp. II) is a biotech company, founded by Robert Wessman.Alvotech are 800 professionals across multiple countries,focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer.
CEO： Mr. Mark Levick
Market： NASDAQ
Listing Date： 09/17/2020
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet